Klin Farmakol Farm. 2003;17(3):174-176

Kombinovaná léčba asthma bronchiale u dětí

František Kopřiva
Dětská klinika LF UP a FN Olomouc

Podstatou dlouhodobé, preventivní a udržovací léčby asthma bronchiale jsou protizánětlivé léky, z nichž nejúčinnějšími jsou inhalační kortikosteroidy. Doporučovanou léčbou v současných standardech léčby astmatu pro perzistující astma je kombinovaná léčba - inhalační kortikosteroid s beta-2 mimetikem s dlouhodobým účinkem (fluticasoni propionas/salmeteroli xinafoas nebo budesonid/formoteroli fumaras), s výhodou podávaná v jednom inhalátoru.

Keywords: bronchial asthma, combination therapy, inhaled corticosteroids, long-acting beta-2 agonists.

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kopřiva F. Kombinovaná léčba asthma bronchiale u dětí. Klin Farmakol Farm. 2003;17(3):174-176.

Podstatou dlouhodobé, preventivní a udržovací léčby asthma bronchiale jsou protizánětlivé léky, z nichž nejúčinnějšími jsou inhalační kortikosteroidy. Doporučovanou léčbou v současných standardech léčby astmatu pro perzistující astma je kombinovaná léčba - inhalační kortikosteroid s beta-2 mimetikem s dlouhodobým účinkem (fluticasoni propionas/salmeteroli xinafoas nebo budesonid/formoteroli fumaras), s výhodou podávaná v jednom inhalátoru.

Combination therapy of pediatric asthma

Based on the understanding of asthma as an inflammatory disease, inhaled corticosteroid therapy is considered the most effective anti-inflammatory treatment. Recommended treatment for persisting asthma according tu current guidelines is a combination of inhaled corticosteroids and long-acting beta-2 agonists (fluticasone propionate/salmeterol or budesonide/formoterol).

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Johansson SG, O´B Hourihane J, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, va Hage-Hamstein M, Wuthrich B. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813-824. Go to original source... Go to PubMed...
    2. Global strategy for asthma management and prevention, Global initiative for asthma. NHLBI/WHO. NIH Publication No. 02-3659, 2002.
    3. Kašák V. Salmeterol/fluticason propionát. Remedia 2000; 10: 12-18.
    4. Kašák V. Fixní kombinace budesonidu s formoterolem. Remedia 2002; 12: 214-218.
    5. Holgate ST. Epithelial damage and response. Clin Exp Allergy 2000; 30 (Suppl 1): 37-41. Go to original source... Go to PubMed...
    6. Remington TL, Haeberlin AM, DiGiovane B Combined budesonide/formoterol turbuhaler treatment of asthma. Ann Pharmacotherap 2002; 36 (12): 1918-1928. Go to original source... Go to PubMed...
    7. Vander Berg NJ, Ossip MS, Hederos CA, Anttila A, Ribeiro BL, Davies PI Salmeterol/fluticasone proprionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe inchildren with asthma. Pediatr Pulmonol 2000; 30 (2): 97-105. Go to original source... Go to PubMed...
    8. Pohunek P. Pediatrické aspekty Globální strategie péče o astma - GINA 2002. Alergie 2002; 4 (Suppl 2): 16-17.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.